{
  "docId": "019de075-7a24-71be-ac51-dd13871aea0a",
  "docSlug": "fd7a76edfe86a80da6108d342915286a",
  "documentTitle": "BioAtla | Investor Presentation Deck | 43 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 43,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a spider plot for target lesion change and a Kaplan-Meier survival curve with a summary table.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7a24-71be-ac51-dd13871aea0a/12",
  "deckHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a",
  "deckJsonHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a.json",
  "deckAnchorHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Change Target Lesion From Baseline (%)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48adb293-d146-4e01-a087-9418f4192327",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Progression-free Survival",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9de90bc-a700-4dfe-9ce2-a99ea9cbedfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.48,
        "x": 0.49,
        "y": 0.78
      },
      "kind": "list",
      "text": "Phase 3 randomized study of pazopanib versus placebo ... Single-arm SARC028 study of pembrolizumab ... Limitations of cross trial comparison",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b6d25f4-3706-4eb5-a536-a501d2d3d887",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "list",
      "text": "Combined Phase 1 & 2: efficacy evaluable = 10 TmPS ≥ 50% ... 5/10 patients achieved PRs ... Responses to BA3011 treatment are durable ... Average prior lines of systemic therapy = 3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f174809d-0d2d-4e43-95c3-de8ff4ca09b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Interim data- Data cut-off of Jan 18, 2023. *Votrient package insert... **DOI: 10.1200/JCO.2019.37.15_suppl.11015...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "277c5f26-af45-4dd3-830b-c14c565f7b3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Undifferentiated Pleomorphic Sarcoma (UPS): ORR 50%, Median PFS 10.9 months",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7f43046-93b1-4dfb-a549-18ba5c84b0c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Phase 1 & Phase 2, part 1 change in target lesion and progression free survival (1.8mg/kg; n=10)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "754013d8-0174-4a7f-ba23-8ecdf8e00691",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "133082c7-85f5-4973-804e-0345a7f317eb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck provides market sizing data for various tumor types",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    },
    {
      "to": 19,
      "from": 11,
      "beatId": "3af527af-8544-4e9d-a8c7-da1d6326498b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging clinical results and traction in multiple tumor types",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 40,
      "from": 8,
      "beatId": "e2a4fdc0-9030-4acb-8ef9-b3ca594561cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines a clear roadmap for BioAtla's pipeline and milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "2e84312e-7551-4fe1-b34e-202074eadb7a",
      "evidence": "The deck presents market sizing data for various tumor types",
      "position": 1,
      "objective": "What are the potential market opportunities for CAB technology?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}